Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHER: Consolidative Surgery and Radiotherapy for Oligometastatic HER2+ Breast Cancer
NCT07053085Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2025
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 3 years. Started Sep 2025; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07053085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053085.